Background
==========

Breast cancer is the most common cancer affecting women. Cancer statistics show that the lifetime risk of breast cancer is as high as 12% in the USA. It was estimated that the number of new cases diagnosed in the USA and Europe in 2015 alone was 230 000 and 470 000, respectively \[[@b1-medscimonit-24-3726]\]. However, in China the estimated number of females who died of breast cancer reached 60 473 \[[@b2-medscimonit-24-3726]\]. Due to its invasive characteristics, breast invasive ductal carcinoma (IDC) has become a leading cause of cancer-related deaths among women worldwide \[[@b3-medscimonit-24-3726]\]. Therefore, the discovery of new markers, especially molecularly detectable ones, is noteworthy \[[@b4-medscimonit-24-3726]\].

Biomarkers such as human epidermal growth factor estrogen receptors (ER), progesterone receptors (PR), receptor 2 (HER2), and Ki67 were detected in our study. HER2 is a key mediator in cell growth, differentiation, and survival \[[@b5-medscimonit-24-3726]\]. HER2 is also a representative marker; approximately 20% of patients with IDC show increased HER2 levels \[[@b6-medscimonit-24-3726]--[@b9-medscimonit-24-3726]\]. In general, HER2-positive tumors had higher histological grade. Furthermore, compared to other tumor subtypes, HER2-positive tumors are more likely to invade lymph nodes \[[@b10-medscimonit-24-3726],[@b11-medscimonit-24-3726]\]. Ki67 is a common proliferation parameter which can be used to predict the rate of multiplication of tumor cells. The expression of Ki67 is often upregulated in proliferating cells. Physicians can determine the growth fraction in clonal cell populations by detecting Ki67 expression \[[@b12-medscimonit-24-3726]\]. In addition, IDC of Luminal types A and type B can be distinguished by Ki67 levels \[[@b13-medscimonit-24-3726]\]. Patients with high Ki67 expression levels are usually recommended to accept clinical treatments \[[@b14-medscimonit-24-3726]\].

ADAMTS, also known as ADAM with thrombospondin motifs, is a family of secreted extracellular protease enzymes. Evidence has suggested that ADAMTS expression is dysregulated in diverse types of cancers, including breast, gastric, lung, and colorectal cancer \[[@b15-medscimonit-24-3726]--[@b18-medscimonit-24-3726]\]. In the human genome, 19 ADAMTS members have been identified. Based on known substrates, ADAMTSs can be sub-grouped according to their characteristics. For instance, ADAMTS8 and ADAMTS20 are categorized in the group of aggrecanases or proteoglycanases, while ADAMTS18 is classified in the orphan enzymes group \[[@b19-medscimonit-24-3726],[@b20-medscimonit-24-3726]\]. ADAMTS8, also known as METH-2, is thought to be an antiangiogenic factor \[[@b21-medscimonit-24-3726]\]. There is a high frequency of promoter methylation in some cancers in which there is downregulation of ADAMTS8 \[[@b22-medscimonit-24-3726],[@b23-medscimonit-24-3726]\]. In a very wide range of tumor tissue types, ADAMTS18 has been observed to be frequently hypermethylated, and a deficiency of it enhances tumorigenesis \[[@b24-medscimonit-24-3726]\]. Relevant research has suggested that ADAMTS20 is correlated with migration of melanoblasts \[[@b25-medscimonit-24-3726]\]. ADAMTS8, 18, and 20 have been shown to be associated with cancer development, yet little is known about the mechanism in tumorigenesis, especially in IDC development.

We conducted this study to investigate the association between ADAMTSs and IDC, and to offer a theoretical basis for new treatment methods for IDC patients.

Material and Methods
====================

Tissue samples
--------------

A total of 278 breast IDC tissue samples were collected from IDC patients who had complete clinical data archived at the Affiliated Cancer Hospital of Zhengzhou University from January 2012 to June 2016, and non-proliferative catheter of breast fibroadenoma (FA) was used as the normal control. Patients had no previous diagnosis of carcinoma, no distant metastases at time of diagnosis, and no evidence of disease within 1 month after primary surgery. Furthermore, patients receiving neo-adjuvant therapy or with carcinoma *in situ* only were excluded. After primary surgery, a representative part of the tumor was macroscopically selected by a pathologist, formalin-fixed, and paraffin-embedded for further study. This study was approved by the Institute Review Ethics committee. Written informed consent was obtained from all participants.

Immunohistochemical (IHC) staining
----------------------------------

We deparaffinized 3-μm--thick continuous sections using xylene I and II for 20 min and then dehydrated them with gradient anhydrous ethanol. The slides were soaked in 50 μl 3% H~2~O~2~ for 20 min, and then were placed into a 1-mM Tris-EDTA (pH=9) water bath (100°C) for 20 min, and cooled to room temperature. After washing with PBS, 50 μl of primary antibody solution (\#PA5-64274, rabbit anti-ADAMTS8/18/20, 1: 100, Thermo Fisher Scientific, Waltham, MA, USA) was added and incubated with the slice at 4°C overnight. The UltraView Universal DAB Detection Kit (\#760-500, Ventana Medical Systems, Tucson, Arizona, USA) was used to detect the rabbit primary antibodies used earlier, then the slides were visualized using hydrogen peroxidase substrate and DAB chromogen, producing a brown precipitate.

Western blot (WB)
-----------------

Total proteins from tissues were extracted using radio immunoprecipitation assay (RIPA) buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 7.8, 1 mM EDTA). Protein concentrations were examined with BCA (Thermo Scientific, Rockford, IL, USA), and the proteins were separated using SDS-PAGE. The proteins were then transferred onto PVDF membranes under a constant current of 200 mA. After blocking for 2 h with 5% non-fat dry milk, membranes were incubated for 2 h with the primary antibodies (mouse anti-ADAMTS8/18/20, 1: 900, Abcam, Cambridge, MA, USA), and incubated with HRP-conjugated secondary antibodies (1: 2000, Abcam, Cambridge, MA, USA) for another 2 h. The membranes were washed with TBST (1: 1000 in 2.5% BSA in TBST, Abcam, USA), and all blots were visualized using ECL (Bio-Rad, Hercules, CA, USA).

Prognostic analysis
-------------------

The prognostic data of participants were collected at follow-up visits of 125 breast IDC patients. The date of the operation was set as the beginning date of follow-up, and time of death after the operation was set as the end of follow-up. By analyzing the relationship between clinical pathological parameters, such as the number of lymphatic metastases, ER, PR, HER2, Ki67, ADAMTS8/18/20, and disease-free survival (DFS) rate and mean survival time, the correlation of clinical pathological parameters and the disease-free survival (DFS) time or overall survival (OS) time of IDC patients could be evaluated.

Statistical analysis
--------------------

SPSS 21.0 software was used to perform statistical analyses. *P*\<0.05 was considered to indicate statistical significance. The chi-squared test was used to compare results between IDC groups, while the Spearman correlation analysis was used for the correlation analysis between ADAMTS 8/18/20 expression and clinical pathological parameters. The relative average densities of proteins are presented as the mean ±SD, and their differences were analyzed by the *t* test. The Kaplan-Meier method was assessed with the log-rank test. Cox's proportional hazards model was used for univariate and multivariate analyses of prognostic values. In DFS analysis, the discovery of recurrence or distant metastatic lesions by imagological examination was considered as the end time. Patient death was considered as the end time of the survival event.

Results
=======

Clinical pathology data of IDC patients
---------------------------------------

The average age in the 278 included cases of breast IDC patients was 49 years. About half of the patients had a ≤2 cm diameter tumor size. Diagnosis of the specimens was made according to the WHO classification of tumors. The number of patients with histological grade level II or III was significantly larger than in level I. Lymphatic metastasis was found in about 62.6% of patients, while 97.5% of patients did not have metastasis in any other areas. In follow-up visits of 125 cases, 9 (7.2%) patients had passed away, and 116 (92.8%) were still alive. Details are listed in [Table 1](#t1-medscimonit-24-3726){ref-type="table"}.

Positive expressions of ADAMTS 8, ADAMTS 18, and ADAMTS 20
----------------------------------------------------------

In 278 cases of breast IDC, the positive expressions of ADAMTS 8, ADAMTS 18, and ADAMTS 20 were 84.5%, 88.8%, and 72.3%, respectively. In 20 cases of FA, the positive expressions of these 3 proteins were 45%, 50%, and 90%, respectively. IHC staining results of breast IDC and non-proliferative catheter of FA are shown in [Figure 1](#f1-medscimonit-24-3726){ref-type="fig"}. Results are generally scored as 0, 1, 2, or 3. Positive cells \<5% scored 0 point, 5--25% scored 1 point, 25--50% scored 2 points, 50--75% scored 3 points, and \> 75% scored 4 points. Immunostaining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. When the staining was heterogeneous, the score was calculated, in which the percent positive rating was multiplied by the intensity rating. Those cells scored 0--1 were considered as negative. Therefore, ADAMTS 8, ADAMTS 18, and ADAMTS 20 were all positively expressed in breast IDC.

Relationship between expressions of ADAMTS8/18/20 and IDC molecular classification
----------------------------------------------------------------------------------

According to the consensus reached at the 2011 St. Gellen Conference, breast IDC is divided into 4 groups -- Luminal A, Luminal B, HER-2, and basal-like groups -- based on expression levels of ER, PR, HER2, and Ki67, respectively. In 278 breast IDC patients, there were 7 (2.5%) cases of Luminal A type, 63 (22.7%) cases of Luminal B type (HER2-), 113 (40.6%) cases of Luminal B type (HER2+), 66 (23.7%) cases of HER2+ type, and 29 (10.4%) cases of basal subtype. Significant ADAMTS20 differences existed between HER2 enriched and basal subtypes (*P*\<0.05, [Table 2](#t2-medscimonit-24-3726){ref-type="table"}).

Relationship between expressions of ADAMTS8/18/20 and clinical pathological parameters of IDC patients
------------------------------------------------------------------------------------------------------

The expression of ADAMTS18 was significantly higher, while ADAMTS20 was lower, in II phase patients than in I phase patients (*P*\<0.01, [Table 3](#t3-medscimonit-24-3726){ref-type="table"}). ADAMTS8 had no significant relation to the histological grading of tumors. Moreover, the positive expressions of ADAMTS8, ADAMTS18, and ADAMTS20 showed no association with patient age, tumor size, or lymphatic metastasis (*P*\>0.05, [Table 3](#t3-medscimonit-24-3726){ref-type="table"}).

Relationship between expressions of ADAMTS8/18/20 and HR, HER2, and Ki67 in IDC
-------------------------------------------------------------------------------

In IDC, ADAMTS8 was closely correlated with HER2 expression and displayed a positive relationship (r=0.139, *P*=0.037). ADAMTS18 was closely related with ER, PR, and Ki67, and displayed a positive relationship (r=0.172, *P*=0.004; r=0.135, *P*=0.026; r=0.179, *P*=0.005). However, ADAMTS20 showed no correlation with HR (including ER and PR), HER2, or Ki67 ([Table 4](#t4-medscimonit-24-3726){ref-type="table"}).

Expressions of ADAMTS8, ADAMTS18, and ADAMTS20 proteins in IDC
--------------------------------------------------------------

Western blot analysis was used to detect the variation in ADAMTS8, ADAMTS18, and ADAMTS20 protein expressions. For ADAMTS8, specific protein bands were observed in the FA group, HER2− group, and HER2+ group (each group contained 10 samples). The relative average grey values were significantly different (*P*\<0.01, *P*\<0.05, [Figure 2A](#f2-medscimonit-24-3726){ref-type="fig"}). For ADAMTS18, specific protein bands were observed in the FA group, HR− group, and HR+ group. The relative average grey value in the HR+ group was significantly higher than in the FA and HR− groups (*P*\<0.01, *P*\<0.01, [Figure 2B](#f2-medscimonit-24-3726){ref-type="fig"}). In addition, protein bands were observed in the FA group, Ki67+ group, and Ki67− group. The relative average grey values had statistically significant differences (*P*\<0.01, *P*\<0.05, [Figure 2C](#f2-medscimonit-24-3726){ref-type="fig"}). Finally, ADAMTS20 protein expression in the HER2+ group was significantly higher than in the basal subtype of IDC, but lower than in the FA group (*P*\<0.05, *P*\<0.05, [Figure 2D](#f2-medscimonit-24-3726){ref-type="fig"}).

Relationship between clinical pathological parameters and prognosis of IDC patients
-----------------------------------------------------------------------------------

A higher ADAMTS8 level indicated worse DFS rate and OS rate (all *P*\<0.01, [Figure 3A, 3B](#f3-medscimonit-24-3726){ref-type="fig"}). However, the levels of ADAMTS18 and ADAMTS20 were not significantly related to the postoperative DFS rate and OS rate (all *P*\>0.05, [Figure 3C--3F](#f3-medscimonit-24-3726){ref-type="fig"}). In all clinical pathological parameters, lymphatic metastasis was the only factor that was significantly related to the postoperative DFS rate and the OS time (*P*\<0.05, [Table 5](#t5-medscimonit-24-3726){ref-type="table"}). The number of lymphatic metastases was inversely proportional to the total postoperative survival time of IDC patients. Lymph node metastasis was also correlated with OS rate (*P*\<0.05, [Table 6](#t6-medscimonit-24-3726){ref-type="table"}).

Discussion
==========

This study elucidated the relationship between ADAMTS8/18/20 and breast IDC by studying the molecular subtypes and clinical pathological parameters of IDC patients. ADAMTS20 was distinctly different between HER2-enriched and basal subtype IDC. ADAMTS8 was associated with HER2 expression and ADAMTS18 was associated with HR (ER and PR) expression and Ki67 expression. ADAMTS18 indicated more a severe histological grade, and ADAMTS20 expression indicated a lower histological grade, but none of the 3 ADAMTS were correlated with lymph node metastasis. Lastly, a higher level of ADAMTS8 was correlated with worse prognosis, while ADAMTS 18 and ADAMTS 20 were not related to IDC prognosis.

Molecular subtypes are based on the expression of biological markers. Since breast cancer has many different patterns of metastasis, biological markers are used to distinguish the relevant variable biological features and clinical outcomes. The main subtypes taken into consideration were Luminal A, Luminal B+, Luminal B−, Basal, and HER2-enriched. Aure et al. \[[@b25-medscimonit-24-3726]\] posited that Luminal A was the most frequent subtype found in breast cancer patients (approximately 40%). Phipps et al. \[[@b26-medscimonit-24-3726]\] suggested that high hormone receptor expression is an important characteristic of Luminal A. Goldhirsch et al. \[[@b27-medscimonit-24-3726]\] and Ejlertsen et al. \[[@b28-medscimonit-24-3726]\] also found that both Ki67 and HER2 expressions in Luminal A were significantly reduced. Compared with other subtypes, Luminal A subtype was the most heterogeneous group with the best prognosis and lowest mutation rate \[[@b29-medscimonit-24-3726],[@b30-medscimonit-24-3726]\]. Our study attempted to identify a correlation between ADAMTS and molecular subtypes, finding that ADAMTS8, ADAMTS18, and ADAMTS20 all had significantly higher rates of positive expression in Luminal A subtype (100%) than in other subtypes, indicating that the 3 ADAMTS family members chosen are correlated with these subtypes.

In the ADAMTS family, the members assessed were proven to have different levels of expression and various effects in breast cancer. In a study examining the expressions of all ADAMTS members in breast cancer \[[@b31-medscimonit-24-3726]\], 7 (ADAMTS1, 3, 5, 8, 9, 10, and 18) were observed to be decreased in breast cancer. Reports on ADAMTS family members with roles in breast cancer have mainly concentrated on ADAMTS1 \[[@b32-medscimonit-24-3726]--[@b36-medscimonit-24-3726]\]. Lu et al. \[[@b36-medscimonit-24-3726]\] found an overexpression of ADAMTS1 in nearly 40% of breast tumors, and also reported that ADAMTS1 had a positive correlation with the risk of bone metastasis. ADAMTS18 is usually regarded as a suppressor of breast cancer \[[@b37-medscimonit-24-3726],[@b38-medscimonit-24-3726]\]. However, few researchers have undertaken studies on how ADAMTSs members affect IDC. Thus, our research focused on ADAMTS18 and 2 other rarely-studied ADAMTS members, analyzing the relationship between them and each clinical pathological parameter of IDC patients. However, expressions of both ADAMTS8 and ADAMTS18 were higher in IDC in the present study. In IDC, we observed that HER2 demonstrated a positive correlation with ADAMTS8, and HR and Ki67 were both positively correlated with ADAMTS18. Moreover, clinical pathological parameters were of great help in the prognostic analysis. In our findings, ADAMTS8 and lymphatic metastasis were both significantly correlated with the postoperative 3-year DFS rate and OS time.

However, the present study has certain limitations. Firstly, the small size of patients, especially the number of normal control patients (patients with FA), was not large enough to reveal other unseen differences. A small sample size may fail to clearly reflect the statistical significance of the relationships suggested. Our research also lacked cell experiments, and thus was unable to observe the direct functions of these 3 proteins involved in the development of IDC. We plan to address these issues in future research. In addition, the expression of ADAMTS8, ADAMTS18, and ADAMTS20 in lymph metastases areas should also be studied further to verify their lack of relationship with IDC tumor molecular classification and clinical pathological parameters. Nevertheless, in the present study, several previously unknown characteristics of ADAMTS family members were explored. We took ADAMTS20 into consideration and gained valuable insights into this.

Conclusions
===========

In conclusion, all ADAMTSs examined in our research had high positive rates in Luminal A subtype. According to our findings, ADAMTS8 was associated with HER2 expression and ADAMTS18 was associated with HR (ER and PR) expression and Ki67 expression. ADAMTS18 indicated a more severe histological grade, and ADAMTS20 expression indicated lower histological grade, but none of these 3 ADAMTS were correlated with lymph node metastasis. In IDC patients, a high ADAMTS8 level predicted worse prognosis of IDC patients. These results may inspire more researchers to study IDC.
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![IHC staining result of ADAMTS8, ADAMTS18, and ADAMTS20 in IDC and non-proliferative character of FA. In IDC, the positive expressions of ADAMTS8 and ADAMTS18 were significantly higher, while ADAMTS20 was lower, compared with those in FA. The sepia sections represent the stained proteins. The results showed that proteins were distributed in both cytoplasm and cytoplasm interstitial, mainly in cytoplasm.](medscimonit-24-3726-g001){#f1-medscimonit-24-3726}

![Western blot results of overexpression of ADAMTS8, ADAMTS18, and ADAMTS20 proteins in IDC tissue samples. (**A**) Specific ADAMTS8 protein bands were observed in the FA group, HER2− group, and HER2+ group. Overexpression of ADAMTS8 was positively correlated with the expression level of HER2. (**B**) Specific ADAMTS18 protein bands were observed in the FA group, HR− group, and HR+ group. Overexpression of ADAMTS18 was positively correlated with the expression level of HR. (**C**) Specific ADAMTS18 protein bands were observed in the FA group, Ki67− group, and Ki67+ group. Overexpression of ADAMTS18 was positively correlated with the expression level of Ki67. (**D**) Specific ADAMTS20 protein bands were observed in the FA group, basal-like group, and HER2+ group. The results indicated that ADAMTS20 in the HER2+ group was higher than in the Basal-like group, but lower than in the FA group.](medscimonit-24-3726-g002){#f2-medscimonit-24-3726}

![Relationship between expressions of ADAMTS8, ADAMTS18, and ADAMTS20 and DFS rate and OS rate. (**A, B**) A high level of ADAMTS8 predicted poor DFS and OS rates. (**C, D**) The expression of ADAMTS18 was not significantly related to DFS or OS rate. (**E, F**) The expression of ADAMTS20 was not significantly related to DFS or OS rate. \* *P*\<0.05 indicates a significant difference.](medscimonit-24-3726-g003){#f3-medscimonit-24-3726}

###### 

Clinicopathologic data of 278 cases of IDC patients.

  The clinical pathological characteristics                 Case number (n=278)
  ------------------------------------------- ------------- ---------------------
  Age (year)                                  \<50          136 (48.9%)
  ≥50                                         142 (51.1%)   
  Diameter of tumor (cm)                      ≤2            154 (55.4%)
  \>2                                         124 (44.6%)   
  Histological grade                          I             17 (6.1%)
  II--III                                     261 (93.3%)   
  Lymphatic metastasis                        No            105 (37.8%)
  Yes                                         173 (62.2%)   
  Other parts metastasis                      No            271 (97.5%)
  Yes                                         7 (2.5%)      
  Survival status                             Survival      116 (92.8%)
  Dead                                        9 (7.2%)      
  Loss to follow-up                           153 (55.0%)   

###### 

Positive rate of ADAMTS8, ADAMTS18 and ADAMTS20 protein expressions in each breast IDC molecular subtyping.

  Subtype             Cases   ADAMTS8   ADAMTS18   ADAMTS20                                                                                                                                     
  ------------------- ------- --------- ---------- ----------------------------------------------------------- ----- ---- ----------------------------------------------------------- ---- ---- -----------------------------------------------------------
  Luminal A           7       7         0                                                                      7     0                                                                7    0    
  Luminal B HER2(−)   63      53        10         0.979[@](#tfn1-medscimonit-24-3726){ref-type="table-fn"}    56    7    0.471[@](#tfn1-medscimonit-24-3726){ref-type="table-fn"}    46   17   0.331[@](#tfn1-medscimonit-24-3726){ref-type="table-fn"}
  Luminal B HER2(+)   113     93        20         0.757[\*](#tfn2-medscimonit-24-3726){ref-type="table-fn"}   100   13   0.937[\*](#tfn2-medscimonit-24-3726){ref-type="table-fn"}   79   34   0.663[\*](#tfn2-medscimonit-24-3726){ref-type="table-fn"}
  HER2 enriched       66      58        8          0.348[&](#tfn3-medscimonit-24-3726){ref-type="table-fn"}    57    9    0.628[&](#tfn3-medscimonit-24-3726){ref-type="table-fn"}    51   15   0.331[&](#tfn3-medscimonit-24-3726){ref-type="table-fn"}
  Basal subtype       29      24        5          0.315[\#](#tfn4-medscimonit-24-3726){ref-type="table-fn"}   27    2    0.106[\#](#tfn4-medscimonit-24-3726){ref-type="table-fn"}   18   11   0.021[\#](#tfn4-medscimonit-24-3726){ref-type="table-fn"}

Compared with Luminal A;

compared with Luminal B HER2(−);

compared with Luminal B HER2(+);

compared with HER2 enriched.

*P*\<0.05 indicated statistical significance.

###### 

The relationship between ADAMTS8, ADAMTS18 and ADAMTS20 protein expressions and clinical pathology parameters of IDC.

  Parameter              Cases   ADAMTS8           ADAMTS18   ADAMTS20                                                                                        
  ---------------------- ------- ----------------- ---------- ----------------- ----------------------------------------------------------- ----------------- -----------------------------------------------------------
  Histological grade                                                                                                                                          
   I                     17      82.4% (14/17)                76.5% (13/17)                                                                 88.2% (15/17)     
   II--III               261     84.7% (221/261)   0.568      95.0% (248/261)   0.002[\*](#tfn6-medscimonit-24-3726){ref-type="table-fn"}   54.0% (141/261)   0.006[\*](#tfn6-medscimonit-24-3726){ref-type="table-fn"}
  Tumor size (cm)                                                                                                                                             
   ≤2                    154     83.1% (128/154)              87.7% (135/154)                                                               70.8% (109/154)   
   \>2                   124     86.3% (107/124)   0.558      90.3% (112/124)   0.651                                                       74.2% (92/124)    0.635
  Age (year)                                                                                                                                                  
   \<50                  136     83.1% (113/136)              87.5% (119/136)                                                               70.6% (96/136)    
   ≥50                   142     86.0% (122/142)   0.558      90.1% (128/142)   0.651                                                       74.0% (105/142)   0.635
  Lymphatic metastasis                                                                                                                                        
   No                    105     88.6% (93/105)               87.6% (92/105)                                                                70.5% (74/105)    
   Yes                   173     82.1% (142/173)   0.16       89.0% (154/173)   0.825                                                       73.4% (127/173)   0.753

*P*\<0.05 indicated statistical significance.

###### 

The correlation between ADAMTS8, ADAMTS18, ADAMTS20 protein expressions and expressions of HR, HER2, Ki67.

         ADAMTS8   ADAMTS18   ADAMTS20                                                                                                                                                                  
  ------ --------- ---------- ---------- ----------------------------------------------------------- ----- ---- ------- ----------------------------------------------------------- ----- ---- -------- -------
  ER                                                                                                                                                                                                    
   +     146       30                                                                                157   19                                                                       111   65            
   −     89        13         0.087      0.153                                                       90    12   0.172   0.004[\*](#tfn7-medscimonit-24-3726){ref-type="table-fn"}   90    12   −0.078   0.2
  PR                                                                                                                                                                                                    
   +     131       27                                                                                141   17                                                                       118   40            
   −     104       16         0.035      0.562                                                       106   14   0.135   0.026[\*](#tfn7-medscimonit-24-3726){ref-type="table-fn"}   83    37   −0.069   0.193
  HER2                                                                                                                                                                                                  
   +     151       28                                                                                156   23                                                                       131   50            
   −     84        15         0.139      0.037[\*](#tfn7-medscimonit-24-3726){ref-type="table-fn"}   91    8    0.036   0.576                                                       70    27   0.027    0.712
  Ki67                                                                                                                                                                                                  
   +     176       28                                                                                188   16                                                                       143   61            
   −     59        15         0.177      0.259                                                       59    15   0.179   0.005[\*](#tfn7-medscimonit-24-3726){ref-type="table-fn"}   58    16   0.026    0.72

*P*\<0.05 indicated statistical significance.

###### 

The relationship between pathological parameters and disease-free survival rate and total survival time.

  Parameter                         Case   Ratio (%)   3-year disease-free survival rate   χ^2^     *P*                                                         Mean survival time (Month)   SE    *P*
  --------------------------------- ------ ----------- ----------------------------------- -------- ----------------------------------------------------------- ---------------------------- ----- -----------------------------------------------------------
  Age (year)                                                                                                                                                                                       
   \<50                             63     42.9        90.5                                                                                                     29                           1.3   
   ≥50                              62     57.1        87.1                                0.408    0.523                                                       29                           1.3   0.813
  Tumor size (cm)                                                                                                                                                                                  
   ≤2                               29     14.3        93.1                                                                                                     25                           0.8   
   \>2                              96     85.7        87.5                                0.345    0.557                                                       31                           1.0   0.55
  Histological grade                                                                                                                                                                               
   I                                12     7.1         91.7                                                                                                     34                           1.7   
   II--III                          113    92.9        88.5                                0.304    0.581                                                       28                           20    0.257
  Number of lymph node metastasis                                                                                                                                                                  
   0                                50     14.3        96.0                                                                                                     34                           1.2   
   1≤L\<4                           43     21.4        93.0                                                                                                     30                           0.7   
   \>4                              32     64.3        71.9                                14.643   0.001[\*](#tfn8-medscimonit-24-3726){ref-type="table-fn"}   26                           2.8   0.004[\*](#tfn8-medscimonit-24-3726){ref-type="table-fn"}

*P*\<0.05 indicated statistical significance.

###### 

The result of multivariate Cox regression analysis on clinicopathologic factors.

  Parameter                         Overall survival (95%CI)   *P*
  --------------------------------- -------------------------- -----------------------------------------------------------
  Age (year)                                                   
   \<50                             1                          
   ≥50                              1.860 (0.348--9.943)       0.468
  Tumor size (cm)                                              
   ≤2                               1                          
   \>2                              2.236 (0.554--10.942)      0.236
  Histological grade                                           
   I                                1                          
   II--III                          4.210 (0.075--2.369)       0.327
  Number of lymph node metastasis                              
   1≤L\<4                           1                          
   \>4                              16.231 (1.171--224.96)     0.038[\*](#tfn9-medscimonit-24-3726){ref-type="table-fn"}

*P*\<0.05 indicated statistical significance.
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